Drug Trial Radar · NCT05037279
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
540
Planned (sponsor's estimate)
Start
Apr 24, 2024
Primary completion
Feb 2029
Study completion Feb 2029
Sponsor
- Lead sponsor
- Verity Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to evaluate the effect of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC) and to compare our findings to the standard of care BCG formulation, OncoTICE (BCG) in order to examine our hypothesis that Verity-BCG is at least non-inferior to OncoTICE in achieving 24-month Recurrence Free Survival in NMIBC patients who are at high risk of recurrence and have never been treated with intradermal or intravesical BCG before, with the exception of tuberculosis vaccination in childhood.
Conditions
- Bladder Cancer
- Bladder Cancer Recurrent
- Neoplasm Recurrence
- Urothelial Carcinoma Bladder
- Urothelial Carcinoma Recurrent
- Non-Invasive Bladder Urothelial Carcinoma
Interventions
Bacillus Calmette-Guerin: Strain Russian BCG-IDrug
* Induction: 80 mg weekly for 6 weeks. * Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. * Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Bacillus Calmette-Guerin: Strain TICEDrug
* Induction: 50 mg weekly for 6 weeks. * Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months. * Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence Free Survival (RFS) at 24 monthsTime frame: 24 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Site 05
Vancouver, British Columbia, Canada · Recruiting
Site 04
Kingston, Ontario, Canada · Recruiting
Site 01
Toronto, Ontario, Canada · Recruiting
Site 02
Toronto, Ontario, Canada · Not yet recruiting
Site 08
Toronto, Ontario, Canada · Recruiting
Site 10
Montreal, Quebec, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.